Doxercalciferol
(Redirected from Hectorol)
Doxercalciferol is a synthetic vitamin D analog that plays a crucial role in the regulation of calcium and phosphorus metabolism. It is primarily used in the treatment of secondary hyperparathyroidism associated with chronic kidney disease (CKD). Doxercalciferol acts by inhibiting the secretion of parathyroid hormone (PTH) by the parathyroid gland, which is often elevated in patients with CKD.
Mechanism of Action[edit | edit source]
Doxercalciferol is activated in the liver to form its active metabolite, 1α,25-dihydroxyvitamin D2. This active form binds to the vitamin D receptor (VDR) in the parathyroid gland, leading to a decrease in PTH secretion. The reduction in PTH levels helps to normalize serum calcium and phosphorus levels, thereby mitigating the risk of bone disease associated with secondary hyperparathyroidism.
Indications[edit | edit source]
Doxercalciferol is indicated for the treatment of secondary hyperparathyroidism in patients undergoing chronic renal dialysis. It is also used in patients with CKD not yet on dialysis to reduce elevated levels of PTH.
Pharmacokinetics[edit | edit source]
After administration, doxercalciferol is rapidly absorbed and undergoes activation in the liver. Its pharmacokinetics may vary among individuals, particularly in patients with liver impairment, which can affect the drug's activation.
Side Effects[edit | edit source]
The use of doxercalciferol can lead to several side effects, including hypercalcemia (high calcium levels in the blood), hyperphosphatemia (high phosphate levels in the blood), and hypercalciuria (high calcium levels in the urine). Monitoring of serum calcium and phosphorus levels is recommended during treatment.
Administration and Dosage[edit | edit source]
Doxercalciferol is available in both oral and intravenous formulations. The dosage is individualized based on the patient's baseline PTH levels, and adjustments are made based on the response and any adverse effects experienced by the patient.
Conclusion[edit | edit source]
Doxercalciferol represents an important option in the management of secondary hyperparathyroidism in patients with CKD. Its ability to effectively reduce PTH levels, while managing calcium and phosphorus balance, makes it a valuable tool in preventing the bone disease associated with this condition.
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD